Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024
July 25, 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Independent Bank Corporation Reports 2024 Second Quarter Results
July 25, 2024 07:59 ET
|
Independent Bank Corporation
Second Quarter Highlights Highlights for the second quarter of 2024 include: Increases in net income and diluted earnings per share of 25.3% and 25.7%, respectively, over second quarter of...
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
July 25, 2024 07:57 ET
|
ZyVersa Therapeutics
WESTON, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
Chemomab Therapeutics Announces $10 Million Private Placement
July 25, 2024 07:38 ET
|
Chemomab Therapeutics
Chemomab announced a $10 million PIPE that enables the company to extend its cash runway until early 2026, well past 2 upcoming milestones in early 2025.
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
July 25, 2024 07:35 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies...
FirstService Reports Second Quarter 2024 Results
July 25, 2024 07:30 ET
|
FirstService Corporation
Operating highlights: Three months ended Six months ended June 30 June 30 2024 2023 2024 2023 Revenues (millions)$1,297.5 $1,119.7 $2,455.5 $2,138.2 Adjusted EBITDA (millions)...
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
July 25, 2024 07:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the...
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
July 25, 2024 07:30 ET
|
23andMe, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy...
Kelly Announces Second-Quarter 2024 Conference Call
July 25, 2024 07:30 ET
|
Kelly Services, Inc.
TROY, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Kelly, a leading global specialty talent solutions provider, will release its second-quarter earnings before the market opens on Thursday, August 8,...
SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
July 25, 2024 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...